153 related articles for article (PubMed ID: 37195148)
1. Transcriptomic evidence for tumor-specific beneficial or adverse effects of TGFβ pathway inhibition on the prognosis of patients with liver cancer.
Desoteux M; Maillot B; Bévant K; Ferlier T; Leroux R; Angenard G; Louis C; Sulpice L; Boudjema K; Coulouarn C
FEBS Open Bio; 2023 Jul; 13(7):1278-1290. PubMed ID: 37195148
[TBL] [Abstract][Full Text] [Related]
2. NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC.
Cao Y; Agarwal R; Dituri F; Lupo L; Trerotoli P; Mancarella S; Winter P; Giannelli G
Cell Death Dis; 2017 Feb; 8(2):e2634. PubMed ID: 28230858
[TBL] [Abstract][Full Text] [Related]
3. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
[TBL] [Abstract][Full Text] [Related]
4. Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression.
Rani B; Malfettone A; Dituri F; Soukupova J; Lupo L; Mancarella S; Fabregat I; Giannelli G
Cell Death Dis; 2018 Mar; 9(3):373. PubMed ID: 29515105
[TBL] [Abstract][Full Text] [Related]
5. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Serova M; Tijeras-Raballand A; Dos Santos C; Albuquerque M; Paradis V; Neuzillet C; Benhadji KA; Raymond E; Faivre S; de Gramont A
Oncotarget; 2015 Aug; 6(25):21614-27. PubMed ID: 26057634
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.
Coulouarn C; Factor VM; Thorgeirsson SS
Hepatology; 2008 Jun; 47(6):2059-67. PubMed ID: 18506891
[TBL] [Abstract][Full Text] [Related]
7. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
8. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE
J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156
[TBL] [Abstract][Full Text] [Related]
9. A TGFβ Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFβ-independent Manner.
Ishigami I; Shuwari N; Kaminade T; Mizuguchi H; Sakurai F
Anticancer Res; 2021 May; 41(5):2431-2440. PubMed ID: 33952468
[TBL] [Abstract][Full Text] [Related]
10. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
11. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.
Yingling JM; McMillen WT; Yan L; Huang H; Sawyer JS; Graff J; Clawson DK; Britt KS; Anderson BD; Beight DW; Desaiah D; Lahn MM; Benhadji KA; Lallena MJ; Holmgaard RB; Xu X; Zhang F; Manro JR; Iversen PW; Iyer CV; Brekken RA; Kalos MD; Driscoll KE
Oncotarget; 2018 Jan; 9(6):6659-6677. PubMed ID: 29467918
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
13. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
[TBL] [Abstract][Full Text] [Related]
14. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Faivre S; Santoro A; Kelley RK; Gane E; Costentin CE; Gueorguieva I; Smith C; Cleverly A; Lahn MM; Raymond E; Benhadji KA; Giannelli G
Liver Int; 2019 Aug; 39(8):1468-1477. PubMed ID: 30963691
[TBL] [Abstract][Full Text] [Related]
15. Regulation of transforming growth factor-beta1 gene expression and cell proliferation in human hepatocellular carcinoma cells (PLC/PRF/5) by tamoxifen.
Gong Y; Zhang M; Minuk GY
J Lab Clin Med; 1999 Jul; 134(1):90-5. PubMed ID: 10402064
[TBL] [Abstract][Full Text] [Related]
16. Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFβ Signaling.
Chen J; Mitra A; Li S; Song S; Nguyen BN; Chen JS; Shin JH; Gough NR; Lin P; Obias V; He AR; Yao Z; Malta TM; Noushmehr H; Latham PS; Su X; Rashid A; Mishra B; Wu RC; Mishra L
Cancer Res; 2020 May; 80(9):1819-1832. PubMed ID: 32127355
[TBL] [Abstract][Full Text] [Related]
17. A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma.
Reiss KA; Wattenberg MM; Damjanov N; Prechtel Dunphy E; Jacobs-Small M; Lubas MJ; Robinson J; Dicicco L; Garcia-Marcano L; Giannone MA; Karasic TB; Furth EE; Carpenter EL; Wojcieszynski AP; Vonderheide RH; Beatty GL; Ben-Josef E
Mol Cancer Ther; 2021 Feb; 20(2):389-397. PubMed ID: 33268571
[TBL] [Abstract][Full Text] [Related]
18. The involvement of lipid raft pathway in suppression of TGFβ-mediated metastasis by tolfenamic acid in hepatocellular carcinoma cells.
Sun J; Tao R; Mao T; Feng Z; Guo Q; Zhang X
Toxicol Appl Pharmacol; 2019 Oct; 380():114696. PubMed ID: 31381904
[TBL] [Abstract][Full Text] [Related]
19. GATA5 inhibits hepatocellular carcinoma cells malignant behaviours by blocking expression of reprogramming genes.
Feng H; Zhu M; Zhang R; Wang Q; Li W; Dong X; Chen Y; Lu Y; Liu K; Lin B; Guo J; Li M
J Cell Mol Med; 2019 Apr; 23(4):2536-2548. PubMed ID: 30672133
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma.
Zhan K; Bai Y; Liao S; Chen H; Kuang L; Luo Q; Lv L; Qiu L; Mei Z
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
